

Kevin O Lillehei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9724703/publications.pdf>

Version: 2024-02-01

31
papers

470
citations

840776

11
h-index

752698

20
g-index

31
all docs

31
docs citations

31
times ranked

600
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive Factors for Surgical Intervention in Prolactinomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.8	0
2	High-Throughput Screening of Meningiomas Identifies Proteasome Inhibition as a Potential Treatment Avenue. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.8	0
3	DNA Methyl Transferase Inhibition in Meningiomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.8	0
4	Algorithmic Multimodality Approach to Diagnosis and Treatment of Spinal CSF Leak and Venous Fistula in Patients With Spontaneous Intracranial Hypotension. American Journal of Roentgenology, 2022, 219, 292-301.	2.2	21
5	Targeting DNA Methyl Transferases with Decitabine in Cultured Meningiomas. World Neurosurgery, 2022, 162, e99-e119.	1.3	1
6	High-Throughput Mechanistic Screening of Epigenetic Compounds for the Potential Treatment of Meningiomas. Journal of Clinical Medicine, 2021, 10, 3150.	2.4	5
7	Cytokine-Laden Extracellular Vesicles Predict Patient Prognosis after Cerebrovascular Accident. International Journal of Molecular Sciences, 2021, 22, 7847.	4.1	4
8	Clinical Features of Pineal Parenchymal Tumors of Intermediate Differentiation (PPTID): A Single-Institution Series. World Neurosurgery, 2021, 155, e229-e235.	1.3	6
9	DDRE-20. HIGH-THROUGHPUT SCREENING OF FDA-APPROVED COMPOUNDS IN GLIOMA AND GLIOBLASTOMA IDENTIFIES NOVEL THERAPEUTICS. Neuro-Oncology, 2021, 23, vi78-vi78.	1.2	0
10	NCMP-14. SKULL BASE OSTEOMYELITIS DUE TO COMMUNITY-ACQUIRED ASPERGILLUS FUMIGATUS MIMICKING RECURRENT CHONDROSARCOMA. Neuro-Oncology, 2020, 22, ii125-ii126.	1.2	0
11	ACTR-54. VIGILANT OBSERVATION OF GLIADEL WAFER IMPLANT (VIGILANT) REGISTRY: INTERIM ANALYSIS. Neuro-Oncology, 2019, 21, vi26-vi26.	1.2	0
12	RARE-02. SYMPTOMATIC SALIVARY GLAND-LIKE TUMORS OF THE SELLAR REGION: ADDITIONAL FEATURES AND REVIEW OF THE LITERATURE. Neuro-Oncology, 2019, 21, vi221-vi221.	1.2	0
13	DDIS-26. HIGH-THROUGHPUT DRUG SCREENING OF MENINGIOMAS IDENTIFIES HDAC INHIBITORS AS PROMISING TARGETS ACROSS GRADES. Neuro-Oncology, 2019, 21, vi68-vi69.	1.2	0
14	Benefit of Intracystic Bleomycin for Symptomatic Recurrent Rathke Cleft Cyst. Operative Neurosurgery, 2019, 17, 268-272.	0.8	1
15	Strategies to reduce readmissions for hyponatremia after transsphenoidal surgery for pituitary adenomas. Endocrine, 2018, 62, 333-339.	2.3	29
16	Review of xanthomatous lesions of the sella. Brain Pathology, 2017, 27, 377-395.	4.1	39
17	Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. Frontiers in Oncology, 2017, 7, 252.	2.8	31
18	Double separate versus contiguous pituitary adenomas: MRI features and endocrinological follow up. Pituitary, 2016, 19, 472-481.	2.9	17

#	ARTICLE	IF	CITATIONS
19	Endoplasmic Reticulum Chaperones and Their Roles in the Immunogenicity of Cancer Vaccines. <i>Frontiers in Oncology</i> , 2015, 4, 379.	2.8	13
20	Differential somatostatin receptor (SSTR) 1â€“5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. <i>Molecular and Cellular Endocrinology</i> , 2015, 417, 73-83.	3.2	50
21	Massive Dissemination From Spinal Cord Gangliogliomas Negative for BRAF V600E. <i>American Journal of Clinical Pathology</i> , 2014, 142, 254-260.	0.7	8
22	Non-small-cell lung cancer with brain metastasis. <i>Oncology</i> , 2004, 18, 1725-8.	0.5	1
23	Ultrasound-Induced hyperthermia increases cellular uptake and cytotoxicity of P-glycoprotein substrates in multi-drug resistant cells. <i>Pharmaceutical Research</i> , 2001, 18, 1255-1261.	3.5	40
24	Latest Advances in the Understanding of Active-Specific Immunotherapy for Brain Tumors. <i>ACS Symposium Series</i> , 2000, , 220-229.	0.5	0
25	Reverse transcription polymerase chain reaction analysis of pituitary hormone, Pit-1 and steroidogenic factor-1 messenger RNA expression in pituitary tumors. <i>Pituitary</i> , 1999, 2, 217-224.	2.9	2
26	Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. , 1998, 69, 76-82.		3
27	Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 1997, 45, 77-87.	4.2	130
28	Intralesionally implanted cisplatin cures primary brain tumor in rats. , 1997, 64, 268-275.		17
29	Intraneural Neurothekeoma. <i>Neurosurgery</i> , 1995, 37, 333-335.	1.1	8
30	Neural cell adhesion molecule expression in human pituitary adenomas. <i>Journal of Neuro-Oncology</i> , 1995, 25, 205-213.	2.9	13
31	Interleukin-2â€“activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro. <i>Cancer</i> , 1989, 64, 1629-1637.	4.1	31